Advertisement

Prostate-Specific Membrane Antigen-Based PET Brings New Insights into the Management of Prostate Cancer

Published:September 21, 2022DOI:https://doi.org/10.1016/j.cpet.2022.07.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to PET Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Siegel R.L.
        • Miller K.D.
        • Fuchs H.E.
        • et al.
        Cancer statistics, 2022.
        CA Cancer J Clin. 2022; 72: 7-33
        • Israeli R.S.
        • Powell C.T.
        • Fair W.R.
        • et al.
        Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen.
        Cancer Res. 1993; 53: 227-230
        • Horoszewicz J.S.
        • Kawinski E.
        • Murphy G.P.
        Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients.
        Anticancer Res. 1987; 7: 927-935
        • Ristau B.T.
        • O'Keefe D.S.
        • Bacich D.J.
        The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.
        Urol Oncol. 2014; 32: 272-279
        • Leek J.
        • Lench N.
        • Maraj B.
        • et al.
        Prostate-specific membrane antigen: evidence for the existence of a second related human gene.
        Br J Cancer. 1995; 72: 583-588
        • Robinson M.B.
        • Blakely R.D.
        • Couto R.
        • et al.
        Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain.
        J Biol Chem. 1987; 262: 14498-14506
        • Nimmagadda S.
        • Pullambhatla M.
        • Chen Y.
        • et al.
        Low-level endogenous PSMA expression in nonprostatic tumor xenografts is sufficient for in vivo tumor targeting and imaging.
        J Nucl Med. 2018; 59: 486-493
        • Haffner M.C.
        • Kronberger I.E.
        • Ross J.S.
        • et al.
        Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers.
        Hum Pathol. 2009; 40: 1754-1761
        • Kinoshita Y.
        • Kuratsukuri K.
        • Landas S.
        • et al.
        Expression of prostate-specific membrane antigen in normal and malignant human tissues.
        World J Surg. 2006; 30: 628-636
        • Bostwick D.G.
        • Pacelli A.
        • Blute M.
        • et al.
        Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
        Cancer. 1998; 82: 2256-2261
        • Silver D.A.
        • Pellicer I.
        • Fair W.R.
        • et al.
        Prostate-specific membrane antigen expression in normal and malignant human tissues.
        Clin Cancer Res. 1997; 3: 81-85
        • Ghosh A.
        • Heston W.D.W.
        Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer.
        J Cell Biochem. 2004; 91: 528-539
        • Hofman M.S.
        • Hicks R.J.
        • Maurer T.
        • et al.
        Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls.
        Radiographics Jan-feb. 2018; 38: 200-217
        • Wang R.
        • Shen G.
        • Yang R.
        • et al.
        68)Ga-PSMA PET/MRI for the diagnosis of primary and biochemically recurrent prostate cancer: a meta-analysis.
        Eur J Radiol. 2020; 130: 109131
        • Rowe S.P.
        • Macura K.J.
        • Ciarallo A.
        • et al.
        Comparison of prostate-specific membrane antigen-based 18F-DCFBC PET/CT to conventional imaging modalities for detection of hormone-naïve and castration-resistant metastatic prostate cancer.
        J Nucl Med. 2016; 57: 46-53
        • Rowe S.P.
        • Macura K.J.
        • Mena E.
        • et al.
        PSMA-based [(18)F]DCFPyL PET/CT is superior to conventional imaging for lesion detection in patients with metastatic prostate cancer.
        Mol Imaging Biol. 2016; 18: 411-419
        • Hu X.
        • Wu Y.
        • Yang P.
        • et al.
        Performance of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography/computed tomography in the diagnosis of primary prostate cancer: a systematic review and meta-analysis.
        Int Braz J Urol. 2021; 47https://doi.org/10.1590/s1677-5538.Ibju.2020.0986
        • Evangelista L.
        • Zattoni F.
        • Cassarino G.
        • et al.
        PET/MRI in prostate cancer: a systematic review and meta-analysis.
        Eur J Nucl Med Mol Imaging. 2021; 48: 859-873
        • Jansen B.H.E.
        • Bodar Y.J.L.
        • Zwezerijnen G.J.C.
        • et al.
        Pelvic lymph-node staging with (18)F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial.
        Eur J Nucl Med Mol Imaging. 2021; 48: 509-520
        • Vlachostergios P.J.
        • Niaz M.J.
        • Skafida M.
        • et al.
        Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer.
        Prostate. 2021; 81: 279-285
        • Kopp J.
        • Kopp D.
        • Bernhardt E.
        • et al.
        68Ga-PSMA PET/CT based primary staging and histological correlation after extended pelvic lymph node dissection at radical prostatectomy.
        World J Urol. 2020; 38: 3085-3090
        • Martinez J.
        • Subramanian K.
        • Margolis D.
        • et al.
        68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: a prospective single-institutional study.
        Transl Oncol. 2022; 15: 101242
        • Xue A.L.
        • Kalapara A.A.
        • Ballok Z.E.
        • et al.
        68)Ga-Prostate-Specific membrane antigen positron emission tomography maximum standardized uptake value as a predictor of gleason pattern 4 and pathological upgrading in intermediate-risk prostate cancer.
        J Urol. 2022; 207: 341-349
        • Sonni I.
        • Eiber M.
        • Fendler W.P.
        • et al.
        Impact of (68)Ga-PSMA-11 PET/CT on staging and management of prostate cancer patients in various clinical settings: a prospective single-center study.
        J Nucl Med. 2020; 61: 1153-1160
        • Abufaraj M.
        • Grubmüller B.
        • Zeitlinger M.
        • et al.
        Prospective evaluation of the performance of [(68)Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.
        Eur J Nucl Med Mol Imaging ∗. 2019; 46: 2169-2177
        • Hofman M.S.
        • Lawrentschuk N.
        • Francis R.J.
        • et al.
        Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.
        Lancet. 2020; 395: 1208-1216
      1. FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer.
        BJU Int. 2021; 128: 127-130
      2. FDA Approves First PSMA-Targeted PET Drug.
        J Nucl Med. 2021; 62: 11n
        • Jadvar H.
        • Calais J.
        • Fanti S.
        • et al.
        Appropriate use criteria for prostate-specific membrane antigen PET imaging.
        J Nucl Med. 2022; 63: 59-68
        • Schöder H.
        • Hope T.A.
        • Knopp M.
        • et al.
        Considerations on integrating prostate-specific membrane antigen positron emission tomography imaging into clinical prostate cancer trials by national clinical trials Network Cooperative groups.
        J Clin Oncol. 2022; : Jco2102440https://doi.org/10.1200/jco.21.02440
        • Gordon L.G.
        • Elliott T.M.
        • Joshi A.
        • et al.
        Exploratory cost-effectiveness analysis of (68)Gallium-PSMA PET/MRI-based imaging in patients with biochemical recurrence of prostate cancer.
        Clin Exp Metastas. 2020; 37: 305-312
        • Xiang M.
        • Ma T.M.
        • Savjani R.
        • et al.
        Performance of a prostate-specific membrane antigen positron emission tomography/computed tomography-derived risk-stratification tool for high-risk and very high-risk prostate cancer.
        JAMA Netw Open. 2021; 4: e2138550
        • Klingenberg S.
        • Jochumsen M.R.
        • Ulhøi B.P.
        • et al.
        68)Ga-PSMA PET/CT for primary lymph node and distant metastasis NM staging of high-risk prostate cancer.
        J Nucl Med. 2021; 62: 214-220
        • Bodar Y.J.L.
        • Jansen B.H.E.
        • van der Voorn J.P.
        • et al.
        Detection of prostate cancer with (18)F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial.
        World J Urol. 2021; 39: 2439-2446
        • Hope T.A.
        • Goodman J.Z.
        • Allen I.E.
        • et al.
        Metaanalysis of (68)Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathology.
        J Nucl Med. 2019; 60: 786-793
        • Langbein T.
        • Wang H.
        • Rauscher I.
        • et al.
        Utility of (18)F-rhPSMA-7.3 positron emission tomography for imaging of primary prostate cancer and pre-operative efficacy in N-staging of unfavorable intermediate to very high-risk patients validated by histopathology.
        J Nucl Med. 2022; https://doi.org/10.2967/jnumed.121.263440
        • Ferraro D.A.
        • Muehlematter U.J.
        • Garcia Schüler H.I.
        • et al.
        68)Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer.
        Eur J Nucl Med Mol Imaging. 2020; 47: 147-159
        • Zhou J.
        • Gou Z.
        • Wu R.
        • et al.
        Comparison of PSMA-PET/CT, choline-PET/CT, NaF-PET/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a systematic review and meta-analysis.
        Skeletal Radiol. 2019; 48: 1915-1924
        • Pomykala K.L.
        • Czernin J.
        • Grogan T.R.
        • et al.
        Total-body 68Ga-PSMA-11 PET/CT for bone metastasis detection in prostate cancer patients: potential impact on bone scan guidelines.
        J Nucl Med. 2020; 61: 405-411
        • Afaq A.
        • Payne H.
        • Davda R.
        • et al.
        A Phase II, Open-label study to assess safety and management change using (68)Ga-THP PSMA PET/CT in patients with high risk primary prostate cancer or biochemical recurrence after radical treatment: the PRONOUNCED study.
        J Nucl Med. 2021; 62: 1727-1734
        • Thompson I.M.
        • Valicenti R.K.
        • Albertsen P.
        • et al.
        Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO guideline.
        J Urol. 2013; 190: 441-449
        • Cornford P.
        • Bellmunt J.
        • Bolla M.
        • et al.
        EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer.
        Eur Urol. 2017; 71: 630-642
        • Han M.
        • Partin A.W.
        • Zahurak M.
        • et al.
        Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
        J Urol. 2003; 169: 517-523
        • van der Toom E.E.
        • Axelrod H.D.
        • de la Rosette J.J.
        • et al.
        Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.
        Nat Rev Urol. 2019; 16: 7-22
        • Song H.
        • Harrison C.
        • Duan H.
        • et al.
        Prospective evaluation of (18)F-DCFPyL PET/CT in biochemically recurrent prostate cancer in an Academic center: a focus on disease localization and changes in management.
        J Nucl Med. 2020; 61: 546-551
        • Rowe S.P.
        • Campbell S.P.
        • Mana-Ay M.
        • et al.
        Prospective evaluation of PSMA-targeted (18)F-DCFPyL PET/CT in men with biochemical failure after radical prostatectomy for prostate cancer.
        J Nucl Med. 2020; 61: 58-61
        • Perera M.
        • Papa N.
        • Roberts M.
        • et al.
        Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis.
        Eur Urol. 2020; 77: 403-417
        • Calais J.
        • Ceci F.
        • Eiber M.
        • et al.
        F-18-fluciclovine PET-CT and Ga-68-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial.
        Lancet Oncol. 2019; 20: 1286-1294
        • Crocerossa F.
        • Marchioni M.
        • Novara G.
        • et al.
        Detection rate of prostate specific membrane antigen tracers for positron emission tomography/computerized tomography in prostate cancer biochemical recurrence: a systematic review and Network meta-analysis.
        J Urol. 2021; 205: 356-369
        • Mena E.
        • Rowe S.P.
        • Shih J.H.
        • et al.
        Predictors of (18)F-DCFPyL-PET/CT positivity in patients with biochemical recurrence of prostate cancer after local therapy.
        J Nucl Med. 2021; https://doi.org/10.2967/jnumed.121.262347
        • Van den Broeck T.
        • van den Bergh R.C.N.
        • Briers E.
        • et al.
        Biochemical recurrence in prostate cancer: the European association of Urology prostate cancer guidelines panel recommendations.
        Eur Urol Focus. 2020; 6: 231-234
        • Dong L.
        • Su Y.
        • Zhu Y.
        • et al.
        The European association of Urology biochemical recurrence risk groups predict findings on PSMA PET in patients with biochemically recurrent prostate cancer after radical prostatectomy.
        J Nucl Med. 2021; https://doi.org/10.2967/jnumed.121.262411
        • Bravi C.A.
        • Fossati N.
        • Gandaglia G.
        • et al.
        Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought.
        Eur Urol. 2020; 78: 661-669
        • Grubmüller B.
        • Baltzer P.
        • D'Andrea D.
        • et al.
        68)Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.
        Eur J Nucl Med Mol Imaging. 2018; 45: 235-242
        • Morris M.J.
        • Carroll P.R.
        • Saperstein L.
        • et al.
        Impact of PSMA-targeted imaging with 18F-DCFPyL-PET/CT on clinical management of patients (pts) with biochemically recurrent (BCR) prostate cancer (PCa): results from a phase III, prospective, multicenter study (CONDOR).
        J Clin Oncol. 2020; 38
        • Wright Jr., G.L.
        • Grob B.M.
        • Haley C.
        • et al.
        Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy.
        Urology. 1996; 48: 326-334
        • Sweat S.D.
        • Pacelli A.
        • Murphy G.P.
        • et al.
        Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
        Urology. 1998; 52: 637-640
        • Evans M.J.
        • Smith-Jones P.M.
        • Wongvipat J.
        • et al.
        Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.
        Proc Natl Acad Sci U S A. 2011; 108: 9578-9582
        • Kratochwil C.
        • Giesel F.L.
        • Eder M.
        • et al.
        [1⁷⁷Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer.
        Eur J Nucl Med Mol Imaging. 2015; 42: 987-988
        • Zang J.
        • Liu Q.X.
        • Sui H.M.
        • et al.
        Lu-177-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer.
        J Nucl Med. 2020; : 61
        • Heinzel A.
        • Boghos D.
        • Mottaghy F.M.
        • et al.
        68)Ga-PSMA PET/CT for monitoring response to (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.
        Eur J Nucl Med Mol Imaging. 2019; 46: 1054-1062
        • Giesel F.L.
        • Hadaschik B.
        • Cardinale J.
        • et al.
        F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients.
        Eur J Nucl Med Mol Imaging. 2017; 44: 678-688
        • Pollard J.H.
        • Raman C.
        • Zakharia Y.
        • et al.
        Quantitative test-retest measurement of Ga-68-PSMA-HBED-CC in tumor and normal tissue.
        J Nucl Med. 2020; 61: 1145-1152
        • Sartor O.
        • de Bono J.
        • Chi K.N.
        • et al.
        Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer.
        N Engl J Med. 2021; 385: 1091-1103
        • Jadvar H.
        The VISION forward: recognition and implication of PSMA-/FDG+ mCRPC.
        J Nucl Med. 2021; https://doi.org/10.2967/jnumed.121.263274
        • Hofman M.S.
        • Violet J.
        • Hicks R.J.
        • et al.
        [Lu-177]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
        Lancet Oncol. 2018; 19: 825-833
        • Hofman M.S.
        • Emmett L.
        • Sandhu S.
        • et al.
        [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
        Lancet. 2021; 397: 797-804
        • Violet J.
        • Sandhu S.
        • Iravani A.
        • et al.
        Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of (177)Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer.
        J Nucl Med. 2020; 61: 857-865
        • Weber M.
        • Kurek C.
        • Barbato F.
        • et al.
        PSMA-ligand PET for early castration-resistant prostate cancer: a retrospective single-center study.
        J Nucl Med. 2021; 62: 88-91
        • Pouliot F.
        • Beauregard J.M.
        • Saad F.
        • et al.
        The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
        BJU Int. 2021; https://doi.org/10.1111/bju.15621
        • Hofman M.S.
        • Iravani A.
        Gallium-68 prostate-specific membrane antigen PET imaging.
        PET Clin. 2017; 12: 219-234
        • Noto B.
        • Büther F.
        • Auf der Springe K.
        • et al.
        Impact of PET acquisition durations on image quality and lesion detectability in whole-body (68)Ga-PSMA PET-MRI.
        EJNMMI Res. 2017; 7: 12
        • Harsini S.
        • Saprunoff H.
        • Alden T.
        • et al.
        The effects of monosodium glutamate on PSMA radiotracer uptake in men with recurrent prostate cancer: a prospective, randomized, double-blind, placebo-controlled intraindividual imaging study.
        J Nucl Med. 2021; 62: 81-87
        • Sheikhbahaei S.
        • Werner R.A.
        • Solnes L.B.
        • et al.
        Prostate-specific membrane antigen (PSMA)-Targeted PET imaging of prostate cancer: an update on important pitfalls.
        Semin Nucl Med. 2019; 49: 255-270
        • Rischpler C.
        • Beck T.I.
        • Okamoto S.
        • et al.
        68)Ga-PSMA-HBED-CC uptake in Cervical, Celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging.
        J Nucl Med. 2018; 59: 1406-1411
        • Usmani S.
        • Ahmed N.
        • Marafi F.
        • et al.
        Molecular imaging in neuroendocrine differentiation of prostate cancer: 68Ga-PSMA versus 68Ga-DOTA NOC PET-CT.
        Clin Nucl Med. 2017; 42: 410-413